United States 116th Congress Status: In Committee Bipartisan · 17 D · 8 R cosponsors

HR 3772 — Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019

Last action — Referred to the Subcommittee on Health.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

Summary

Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2020 and as adjusted based on a specified fee schedule factor in each year thereafter.

Bill Text

How this bill changes current law

3 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill adds provisions for separate payment for certain diagnostic radiopharmaceuticals under Medicare.

  • Section 1833(t)(16)

    (G) Separate payment for certain diagnostic radiopharmaceuticals.-- (i) In general.--Notwithstanding any other provision of this subsection, with respect to services furnished on or after January 1, 2020, the Secretary shall not package, and shall make a separate payment as specified in clause (ii) for, a diagnostic radiopharmaceutical defined in clause (v) with an estimated mean per day product cost equal to or exceeding the threshold specified in clause (iii). (ii) Separate payment.--For purposes of clause (i), payment specified in this clause for a diagnostic radiopharmaceutical described in clause (i) shall be equal to-- (I) the average sales price for the drug established under section 1847A, to the extent the average sales price is available, as calculated and adjusted by the Secretary to the extent such adjustment is adopted for other specified covered outpatient drugs under paragraph (14)(A); or (II) if the data necessary to calculate the average sales price for the drug in the year under the sections specified in subclause (I) is not available, the wholesale acquisition cost as defined in subsection 1847A(c)(6)(B), or, if the wholesale acquisition cost is not available, the mean unit cost data derived from hospital claims data. (III) Nothing in this subparagraph shall be construed as affecting eligibility of diagnostic radiopharmaceuticals for pass-through payments under paragraph (6). (iii) Threshold.--For purposes of this subparagraph, the threshold specified in this clause-- (I) for 2020, is $500; and (II) for subsequent years, is the amount specified in this clause for the preceding year increased by the percentage of the OPD fee schedule increase factor under paragraph (3)(C)(iv) for the applicable year. (iv) Budget neutrality.--The Secretary shall make such adjustments as are necessary under subparagraph 9(B) to ensure that the amount of expenditures under this subsection for such year with application of this subparagraph is equal to the amount of expenditures that would be made under this subsection for such year without application of this subparagraph. (v) Definition.--For purposes of this subparagraph, a diagnostic radiopharmaceutical is a drug or biological that is described in section 315.2(a) of title 21, Code of Federal Regulations, or any successor regulation, and is approved by the Food and Drug Administration on or after January 1, 2008.

    This provision establishes new criteria for separate payments for certain diagnostic radiopharmaceuticals under Medicare, ensuring they are compensated independently based on cost thresholds.

  • Section 1833(t)(8)(E)

    AND SEPARATE PAYMENTS FOR CERTAIN DIAGNOSTIC RADIOPHARMACEUTICALS

    This change updates the heading to reflect the addition of separate payments for diagnostic radiopharmaceuticals.

  • Section 1833(t)

    and subparagraph (16)(G)

    This addition ensures that the provisions for separate payments for diagnostic radiopharmaceuticals are included in the relevant adjustments.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  4. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. Referred to the Subcommittee on Health.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 24 co-sponsors · 522 not signed on

Sponsors (1)

Co-sponsors (24)

Not signed on (522)

522 members have not signed on to this bill.

Show all 522 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 3772 do?
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2020 and as adjusted based on a specified fee schedule factor in each year thereafter.
Who sponsors HR 3772?
HR 3772 is sponsored by Peters, Scott H. (Democratic), Rush, Bobby L. (Democratic), Holding, George (Republican), Lieu, Ted (Democratic), McGovern, James P. (Democratic), Burchett, Tim (Republican), Loebsack, David (Democratic), Soto, Darren (Democratic), Slotkin, Elissa (Democratic), Moulton, Seth (Democratic), Rouda, Harley (Democratic), Phillips, Dean (Democratic), Krishnamoorthi, Raja (Democratic), Watson Coleman, Bonnie (Democratic), Brooks, Susan W. (Republican), Lowenthal, Alan S. (Democratic), Rutherford, John H. (Republican), Sewell, Terri A. (Democratic), Murphy, Gregory F. (Republican), Kuster, Ann M. (Democratic), Walorski, Jackie (Republican), Blunt Rochester, Lisa (Democratic), Posey, Bill (Republican), Reschenthaler, Guy (Republican), and Payne, Donald M. (Democratic).
What is the current status of HR 3772?
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HR 3772?
Track HR 3772 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 3772

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 3772

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →